Navigation Links
BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products
Date:4/7/2009

ARLINGTON, Va., April 7 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. In this report, BioInformatics, LLC (http://www.gene2drug.com), the premier research and advisory firm serving the life science market, fielded a detailed 60-question survey to scientists worldwide about their current--and planned--areas of stem cell research, usage of stem cell products and preferred suppliers.

The report is scheduled to release at the end of April, and is available at pre-release pricing until May 17, 2009. This special pricing is at a significant reduction off the regular pricing which will take effect on Monday, May 18, 2009.

Scientists involved in stem cell research, whether they are more focused on understanding basic stem cell biology, developing cell-based therapies using stem cells, or using stem cells to improve drug target validation and toxicology screening, rely on stem cell research products from major life science suppliers as well as more niche stem cell companies. In this report, scientists specify percentage of stem cell culture products purchased from each of the following suppliers:

    ATCC
    BD Biosciences (a part of Becton, Dickinson and Co., NYSE:  BDX)
    CellGenix
    Life Technologies (Nasdaq:  LIFE)
    Lonza (SWX: LONN)
    Millipore (NYSE:  MIL)
    Miltenyi Biotec
    R&D Systems (division of TECHNE Corp., Nasdaq:  TECH)
    Sigma-Aldrich (divisions: SAFC Biosciences, Nasdaq:  SIAL)
    Stem Cell Sciences (AIM:  STEM)
    Stemcell Technologies
    Thermo Fisher Scientific (Hyclone, NYSE:  TMO)
    Zen Bio

Life science suppliers can use this study to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure a leading position in this expanding market. The report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers.

"There is tremendous excitement, especially in the academic community, over the recent Executive Order signed by President Barack Obama rescinding the restriction on federal funding of human embryonic stem cell research," notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. "However, the exploration of induced pluripotent stem cells and the pursuit of cell-based therapies and drug discovery and development research using adult human stem cells continues to provide great promise." Dr. Zemlo has been the senior analyst on over 80 syndicated market research reports, and consulted with multiple stem cell product vendors to optimize the relevance of this study with regards to the current stem cell research market. According to Zemlo, the report provides insights into the origins and sources of stem cells currently used in the lab (adult, embryonic, induced and pluripotent), and those likely to be used over the next several years -- in addition to differentiated cell types and associated diseases under investigation -- allowing suppliers to anticipate the types of stem cell culture products labs will need to purchase.

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/201/.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 42,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    For more information contact:

    Mary Follin
    Manager, Marketing/Sales
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13 (phone)
    m.follin@gene2drug.com
   http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009
2. Virginia Tech Report Has National Importance
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
5. Haemacure Reports Third Quarter 2007 Results
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Biotech Finishes on a High in August, Burrill Report Says
8. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. MDS Reports Third Quarter 2007 Results
11. First New York/New Jersey Health Care Report Card Released
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/9/2017)... Dealmed Medical Supplies, New York ... supplies, drugs, vaccines, and specialty medical products and services, ... to acquire Vantage Medical Supplies, a major distributor of ... New York . ... medical practices, will operate under the Dealmed name as ...
Breaking Medicine Technology: